Tenax Therapeutics, Inc. (TENX)
| Market Cap | 31.75M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -32.09M |
| Shares Out | 25.20M |
| EPS (ttm) | -2.22 |
| PE Ratio | n/a |
| Forward PE | 3.63 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 131,612 |
| Open | 1.32 |
| Previous Close | 1.29 |
| Day's Range | 1.26 - 1.27 |
| 52-Week Range | 0.95 - 3.68 |
| Beta | 2.07 |
| Analysts | Buy |
| Price Target | 4.75 (+277.0%) |
| Earnings Date | Nov 15, 2021 |
About TENX
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company develops levosimendan, which completed a phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction; and Imatinib, a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeu...
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for TENX stock is "Buy." The 12-month stock price forecast is 4.75, which is an increase of 276.98% from the latest price.
News
Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascula...
Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. today announced that the FDA has reviewed and cleared its Investigational New Drug (IND) application for imatinib.
Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announced company to present at H.C. Wainwright Conference September 13-15, 2021
Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) announces second quarter 2021 financial results and provides business update.
Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patient...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces article in Journal of Cardiac Failure identifying novel mechanism of action in Phase 2 HELP Study
Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces Levosimendan in PH-HFpEF webinar on Aug. 16th at 10 am, with Drs. Daniel Burkhoff & Stuart Rich.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fid...
New York, New York--(Newsfile Corp. - July 16, 2021) - Levi & Korsinsky announces it has commenced an investigation of Tenax Therapeutics, Inc (NASDAQ: TENX) concerning possible breaches of fiduciary du...
Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces retirement of CEO Anthony A. DiTonno, Christopher T. Giordano as new CEO and $10 million PIPE.
Tenax Therapeutics Set to Join Russell Microcap® Index
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces inclusion in the Russell Microcap® Index after the U.S. market opens on June 28, 2021
Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces first quarter 2021 financial results and provides business update.
Tenax Announces Publication Titled “Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax announced the publication of positive data from the company's Phase 2 HELP Study in the Journal of American College of Cardiology: Heart Failure
Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to N...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax announced that Ronald R. Blanck, D.O., Gregory Pepin and Chris A. Rallis have voluntarily agreed to step down from the Board of Directors.
Tenax Therapeutics Reports Fiscal Year 2020 Results and Provides Business Update
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) today reported financial results for the year ended December 31, 2020 and provided a business update
Tenax Therapeutics to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) to present company overview at H.C. Wainwright Global Life Sciences Virtual Conference held March 9-10, 2021
Tenax Therapeutics, Inc. Expands Board of Directors
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) appoints June Almenoff, MD, PhD, Michael Davidson, MD, Delcan Doogan, MD, and Stuart Rich, MD to its Board.
Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) to host conf. call & live audio webcast on Jan 21, 2021, at 4:30 pm to discuss acquisition of PH Precision Med
Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today
A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus NV...
TENX Stock: 8 Things to Know About Tenax Therapeutics and PH Precision Med as Shares Rocket
Tenax Therapeutics (TENX) stock is flying high on Tuesday after announcing it has acquired biotech company PH Precision Med. The post TENX Stock: 8 Things to Know About Tenax Therapeutics and PH Precisi...
Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) acquires PH Precision Med (PHPM), adding imatinib to its pipeline. Stuart Rich, MD joins as CMO.
Tenax Therapeutics Reports Third Quarter 2020 Results and Provides Business Update
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) today reported financial results for the third quarter 2020 and provided a business update
Tenax Therapeutics Announces Presentation of 24-Hour HELP Study Results at the American Heart Association Scientific ...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces HELP Study presented at American Heart Association (AHA) Scientific Sessions available Nov. 13th
Tenax Therapeutics to Host Virtual R&D Webinar with Scientific Experts Highlighting HELP Study Results
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) will host a virtual R&D webinar for analysts and investors on Wednesday, November 18, 2020 at 4:30 p.m. EST
Tenax Therapeutics Gains North American Rights to Oral Levosimendan through Expanded License Agreement with Orion Cor...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) announces amendment to Orion License Agreement adding oral levosimendan.
Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) announces presentation of Phase 2 HELP Study at virtual meeting of HFSA on Saturday, Oct 3, 2020 @ 4:30 pm EDT
Tenax Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc.